In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsIn vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesPhenolic composition and medicinal usage of Psidium guajava Linn.: Antifungal activity or inhibition of virulence?Epidemiology of invasive candidiasis: a persistent public health problemIn vitro activity of caspofungin against Candida albicans biofilms.Antifungal susceptibility testing: practical aspects and current challenges.Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformansIn vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effectCompartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometryAntifungal pharmacodynamics: review of the literature and clinical applications.Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitroPharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studiesAntifungal resistance among Candida species.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Investigational antifungal agents.Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.Caspofungin: first approved agent in a new class of antifungals.Systemic antifungal therapy: new options, new challenges.Antifungal pharmacokinetics and pharmacodynamicsOccidiofungin's chemical stability and in vitro potency against Candida species.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Combination treatment of invasive fungal infections.Caspofungin: an overview.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleThe echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The pharmacology and clinical use of caspofungin.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolateExperiences with the use of caspofungin in paediatric patients.Antifungal activity of Cymbopogon winterianus jowitt ex bor against Candida albicansInvasive fungal infections in the ICU.
P2860
Q27025299-0F8827F2-0662-415B-878E-4B62B63778B0Q28345261-2DEEE21D-89B9-414B-A1D4-F325CC49D7E2Q28817992-7290BA82-9904-4690-9E8B-A5F6B8210C72Q29616758-31020163-5DEA-49CA-9E90-782870728636Q31114513-959D94DD-5DAF-4C5A-B5D0-456CA5AC8187Q33975757-EA104664-6DA0-404A-94B5-6C021E657592Q33979304-6573CE8A-BC62-4735-9F43-E670F68569B4Q33980861-EAF8724D-3535-4C7B-80E7-193A18A92E52Q33981480-683ABD99-2142-448B-9B5E-AE79B03C31B1Q33983506-7B643EDF-03D7-4DE9-8E2A-C2893608419BQ34042198-5228D2E6-0411-4988-8498-CF8FCF6BB300Q34083129-D7A7EDA2-D97A-4A00-9A13-C60EC8C7D8CCQ34112321-3BCFBDD3-C082-48FC-8CFC-B89AE2C9863BQ34228214-6A25AADA-8F57-4A41-AB11-F5717F3F69DDQ34253266-962CC323-3F55-4C09-ABE8-52C10A7356FCQ34335225-6D1893F5-235E-41F5-88E9-CA053383BEFBQ34335230-7F4A1E20-6CE4-420D-AB39-737AF9BA479CQ34335243-20AC0411-5CEB-458B-9EAB-8A126BA7752EQ34481664-674C8F1D-F627-475F-8662-33B2FFDF6CC0Q34749364-03A9B930-2EF1-4660-A6F1-785839F05CF3Q34881309-4EDF2516-79B6-43DE-8FF3-5D6A1D46B6C2Q35124726-9D4B387C-2F79-4AB6-982D-20958908C613Q35585219-8994C527-F057-4916-8DB1-B9E85F680B86Q35663841-42B5AD93-6B2F-48BC-9C97-B9A3FACE7D69Q35689277-4207ED76-3EBD-4BCC-A7AD-4A7DDF49EDF1Q35745822-8E46F907-B10D-42D6-83FE-8ED2E7D71327Q36011378-01F0A379-3043-400C-81CA-CC5A61066A6EQ36278031-AEB94A25-23C9-466A-88D9-CBD0E3F59876Q36425025-FC2F1942-411B-4E1A-B207-67A0BA19A966Q36441524-E7D1D20E-754B-462A-9DCB-0B1803489C33Q36491819-C50707D2-8C27-49F0-8752-521AF84F14A8Q36521993-6A3107D4-5F2D-4F23-9E97-B8EF969F51DFQ36626518-C6686EB3-ABD0-4E1C-8A26-E75F0C1138B2Q36788428-CFEB3D54-4957-44DD-B5A0-3EC0BBB79AB8Q36845482-273E9C64-C18E-4A3F-9ECE-1063F2E267F6Q36932989-11C9F68E-2E44-44A7-B64A-E950808A2484Q37159301-9020F332-0C1C-4623-BE76-33D13540AAF5Q37159589-7A3BB5B4-45D1-492A-87F8-A74B3DB3EE56Q37162258-743992E4-B64A-417D-9FB5-43B3FB580443Q37643057-5DB0EA3B-F4F8-4493-882D-12376C2907F5
P2860
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@ast
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@en
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@nl
type
label
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@ast
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@en
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@nl
prefLabel
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@ast
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@en
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@nl
P2093
P1476
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
@en
P2093
M A Pfaller
M E Klepser
S A Messer
P356
10.1016/S0732-8893(98)00130-8
P407
P577
1999-02-01T00:00:00Z